Each tablet contains:

active ingredients: Glimepiride – 2 mg, Metformin hydrochloride – 500 mg; For a full list of excipients see section List of Excipients.

Typically the dose of medicine Dinga should be determined by the target glucose concentration in blood. It is necessary to take the lowest dose that would be sufficient to achieve the desired metabolic control.

During treatment with medicine Dinga concentration of glucose in blood should be regularly determined. In addition, regular control of percentage of glycated hemoglobin is also recommended.

Incorrect administration of the medicine, such as skipping of the next dose, should never be replenished by subsequent administration of higher doses.

Actions of the patient in case of mistakes while taking the medicine (in particular in case of skipping of the next dose of Dinga or skipping of a meal), or in the situations where there is no possibility to take the medicine, should be consulted in advance between the patient and the physician.

Since improvement in metabolic control is associated with increased sensitivity of tissues to insulin, the need for glimepiride may decrease in the course of treatment with Dinga. In order to avoid development of hypoglycemia, the dose should be promptly reduced or administration of Dinga should be stopped.

Dinga should be taken once or twice a day during a meal.

Maximum single dose of metformin is 1000 mg. Maximum daily dose: 8 mg – for glimepiride and 2 000 mg – for metformin.

Only for a small number of patients more effective daily dose is more than 6 mg of glimepiride. Initial dose of Dinga should not exceed daily dose of glimepiride and metformin already being taken by a patient in order to avoid hypoglycemia. When transferring patients taking the combination of glimepiride and metformin monotherapies to Dinga, dose of Dinga will be determined on the basis of doses of glimepiride and metformin taken already, as separate preparations.

If increase of the dose is necessary, daily dose of Dinga should be titrated in increments of only ½ tablet of 2 mg + 500 mg.

Duration of treatment

Typically, treatment with Dinga is carried out for a long time.

Use in pediatric patients

Safety and efficacy of the medicine was not studied in children with diabetes mellitus type 2.

Use in elderly patients

Metformin is excreted mainly by the kidneys. Since there is the risk of development of severe adverse reactions to metformin in patients with impaired renal function, the medicine can only be used in patients with normal renal function. Due to the fact that renal function is reduced with age, metformin should be used with caution. You should carefully select the dose and ensure thorough and regular monitoring of renal function.

Pharmacological group: Oral hypoglycemic agent for combined use (biguanide+sulfonylureas)

ATC group: A10BD02

List of excipients:

• lactose monohydrate
• sodium carmellose
• povidone
• magnesium stearate
• sodium starch glycolate
• microcrystalline cellulose

For more detailed information about the drug, click: http://pharm.cals.am/pharm/data/drug_134482/1734095746965.pdf